Edgewise Therapeutics, Inc.
Business
Edgewise Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule precision medicines for serious muscle diseases. The company's lead program, sevasemten, is an orally administered fast myosin inhibitor in late-stage trials for Duchenne and Becker muscular dystrophies; EDG-7500 is a cardiac sarcomere modulator in Phase 2 trials for hypertrophic cardiomyopathy; and EDG-15400 targets heart failure with preserved ejection fraction. Edgewise operates globally, retaining all development and commercialization rights internally.
Summary from 10-K filed 2026-02-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Research and development | 151 | 127 | 91 | 54 | 32 | |
| General and administrative | 40 | 32 | 23 | 18 | 11 | |
| Total operating expenses | 191 | 159 | 114 | 72 | 43 | |
| Loss from operations | −191 | −159 | −114 | −72 | −43 | |
| Interest income | 24 | 25 | 14 | 4 | 402,000 | |
| Total other income | 24 | 25 | 14 | 4 | 402,000 | |
| Net loss | −168 | −134 | −100 | −68 | −43 | |
| Unrealized gain on available-for-sale securities | 257,000 | 321,000 | 1 | −841,000 | −514,000 | |
| Total comprehensive loss | −168 | −133 | −99 | −68 | −43 | |
| Net loss per share, basic (in dollars per share) | −1.63 | −1.45 | −1.57 | — | — | |
| Net loss per share, diluted (in dollars per share) | −1.63 | −1.45 | −1.57 | — | — | |
| Weighted-average shares outstanding, basic (in shares) | 103 | 92 | 64 | 54 | 38 | |
| Weighted-average shares outstanding, diluted (in shares) | 103 | 92 | 64 | 54 | 38 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 61 | 42 | 86 | 22 | 16 | |
| Marketable securities, available for sale | 469 | 429 | 232 | 330 | 265 | |
| Prepaid expenses and other assets | 13 | 5 | 9 | 5 | 3 | |
| Total current assets | 543 | 475 | 327 | 357 | 284 | |
| Property and equipment, net | 8 | 10 | 10 | 9 | 912,000 | |
| Operating lease right-of-use asset | 1 | 2 | 2 | 1 | — | |
| Other non-current assets | — | 262,000 | 348,000 | 251,000 | 548,000 | |
| Total assets | 553 | 487 | 340 | 367 | 285 | |
| Accounts payable | 6 | 6 | 4 | 6 | 4 | |
| Accrued compensation | 12 | 10 | 6 | 4 | 3 | |
| Accrued other expenses | 8 | 7 | 6 | 6 | 4 | |
| Operating lease liability, current portion | 1 | 996,000 | 980,000 | 608,000 | — | |
| Total current liabilities | 27 | 24 | 17 | 17 | 11 | |
| Operating lease liability, net of current portion | 3 | 4 | 4 | 4 | — | |
| Total liabilities | 30 | 28 | 21 | 20 | 11 | |
| Commitments and contingencies (see note 5) | — | — | — | — | — | |
| Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of December 31, 2025 and December 31, 2024 | — | — | — | — | — | |
| Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 106,249,579 shares and 94,838,466 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 10,000 | 9,000 | 7,000 | 6,000 | 5,000 | |
| Additional paid-in capital | 1,068 | 837 | 563 | 493 | 352 | |
| Accumulated other comprehensive income | 677,000 | 420,000 | 99,000 | −1 | −514,000 | |
| Accumulated deficit | −546 | −379 | −245 | −145 | −77 | |
| Total stockholders' equity | 522 | 459 | 319 | 347 | 274 | |
| Total liabilities and stockholders' equity | 553 | 487 | 340 | 367 | 285 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Net loss | −168 | −134 | −100 | −68 | −43 | |
| Depreciation | 2 | 2 | 2 | 400,000 | 300,000 | |
| Stock-based compensation | 35 | 25 | 18 | 11 | 4 | |
| Accretion of discount on marketable securities, net | −8 | −13 | −10 | −543,000 | — | |
| Amortization of right-of-use asset | 182,000 | 221,000 | 181,000 | 170,000 | — | |
| Prepaid expenses and other assets | −8 | 3 | −4 | −1 | −2 | |
| Accounts payable | 272,000 | 2 | −92,000 | 47,000 | 3 | |
| Accrued compensation | 2 | 4 | 2 | 1 | 2 | |
| Accrued other expenses and other liabilities | 691,000 | 1 | 526,000 | 1 | 3 | |
| Lease liability | −748,000 | −220,000 | −104,000 | 3 | — | |
| Net cash used in operating activities | −144 | −109 | −92 | −53 | −34 | |
| Purchases of marketable securities | −527 | −477 | −256 | −292 | −288 | |
| Sales of marketable securities | 67 | 16 | 20 | — | — | |
| Maturities of marketable securities | 427 | 278 | 344 | — | — | |
| Purchases of property and equipment | −256,000 | −1 | −6 | −6 | −668,000 | |
| Net cash (used in) provided by investing activities | −33 | −185 | 103 | −71 | −242 | |
| Proceeds from issuance of common stock, net of offering costs | 187 | 239 | 53 | 129 | — | |
| Exercise of stock options | 8 | 9 | 117,000 | 405,000 | 112,000 | |
| Payment of deferred offering costs | — | −262,000 | −165,000 | −251,000 | — | |
| Proceeds from Employee Stock Purchase Plan | 923,000 | 888,000 | 596,000 | 320,000 | 248,000 | |
| Net cash provided by financing activities | 196 | 249 | 53 | 130 | 186 | |
| Net change in cash and cash equivalents | 19 | −44 | 64 | 6 | −89 | |
| Right-of-use asset obtained in exchange for new operating lease liability, net of tenant improvement receivable | — | — | 1 | 1 | — | |
| Property and equipment purchases included in accounts payable and accrued other expenses | 199,000 | 44,000 | 227,000 | 3 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Edgewise Therapeutics, Inc.'s CIK number?
Edgewise Therapeutics, Inc.'s SEC CIK number is 0001710072 (1710072). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Edgewise Therapeutics, Inc.'s SEC filings?
All of Edgewise Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Edgewise Therapeutics, Inc. last report earnings?
Edgewise Therapeutics, Inc. (EWTX) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001104659-26-056783). This is Edgewise Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Edgewise Therapeutics, Inc.'s most recent earnings 8-K?
Edgewise Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001104659-26-056783. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Edgewise Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →